ANALYSIS: Deciphering Trulicity’s Indian Premium Price Strategy

Eli Lilly's once-weekly diabetes therapy Trulicity appears to have made its Indian debut priced at a premium compared with certain Western markets - an indication that some innovator firms are less likely to consider major pricing flexibilities in first-wave markets for new products, even if these are emerging economies.